$339.85
Value $308B
UNH and VCYT stock compared: price, dividend, valuation and results, from SEC filings.
$339.85
Value $308B
$25.13
Value $2.0B
UnitedHealth (UNH) has a market value of $308B and Veracyte (VCYT) $2.0B. Over the last year, with dividends, UNH moved +12.9% and VCYT -37.1%. The P/E is 19.4 for UNH and 15.7 for VCYT. Dividend yield: UNH 2.67%, VCYT none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
UNH$308B
VCYT$2.0B
UNH is 154 times VCYT
Revenue, 12 months
UNH$450B
VCYT$582M
UNH is 773 times VCYT
Net income, 12 months
UNH$15.9B
VCYT$127M
UNH is 125 times VCYT
Operating margin
UNH5.3%
VCYT17.1%
11.8 points apart
ROIC
UNH11.3%
VCYT5.8%
5.5 points apart
P/E
UNH19.4
VCYT15.7
UNH is 1.2 times VCYT
Dividend yield
UNH2.7%
VCYT0.0%
2.7 points apart
5-year return
UNH-15.4%
VCYT-49.0%
33.6 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
UNH-15.4%
VCYT-49.0%
| Period | UNHWith dividends | VCYTWith dividends |
|---|---|---|
| 1 year since November 19, 2025 | +12.9%Price +10.0% | -37.1%Price -37.1% |
| 3 years since November 20, 2023 | -32.4%-12.2% a yearPrice -36.5% | -3.5%-1.2% a yearPrice -3.5% |
| 5 years since November 19, 2021 | -15.4%-3.3% a yearPrice -22.8% | -49.0%-12.6% a yearPrice -49.0% |
| 10 years since November 21, 2016 | +166.8%+10.3% a yearPrice +125.9% | +228.5%+12.6% a yearPrice +228.5% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
UNHUnitedHealthVCYTVeracyte
| Price | $339.85 | $25.13 |
|---|---|---|
| Market value | $308B | $2.0B |
| Enterprise value (EV) | $354B | $1.8B |
| P/E | 19.4 | 15.7 |
| P/E, 5-year median | 25.0 | – |
| P/B | 3.0 | 1.4 |
| EV/EBIT | 14.8 | 18.1 |
| Free cash flow yield | 7.4% | 8.1% |
| Revenue, 12 months | $450B | $582M |
|---|---|---|
| Net income, 12 months | $15.9B | $127M |
| Free cash flow, 12 months | $22.8B | $162M |
| Earnings per share, 12 months | $17.52 | $1.54 |
| Revenue growth, year on year | 11.8% | 16.0% |
| Revenue growth a year, past | +11.7%over 5 years | +34.5%over 5 years |
| EPS growth a year, past | -3.8%over 5 years | – |
| Gross margin | 88.3% | 72.0% |
|---|---|---|
| Operating margin | 5.3% | 17.1% |
| Net margin | 3.5% | 21.8% |
| ROIC | 11.3% | 5.8% |
| ROE | 15.5% | 9.4% |
| Cash | $28.5B | $200M |
|---|---|---|
| Total debt | $74.3B | $41M |
| Net debt / EBITDA | 1.6 | -1.7 |
| Interest cover | 6.2× | – |
| Dividend yield | 2.7% | – |
|---|---|---|
| Dividend per share, 12 months | $9.06 | – |
| Dividend growth a year, past | +12.6%over 5 years | – |
| Buyback yield | 1.8% | – |
| Shareholder yield | 4.5% | – |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, UnitedHealth ($308B) is about 154.5 times Veracyte ($2.0B), at today's prices.
Since November 21, 2016, UNH's price moved +125.9% and VCYT's +228.5%. With dividends: UNH +166.8% (+10.3% a year), VCYT +228.5% (+12.6% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.67% for UnitedHealth and none for Veracyte. Over the last twelve months they paid $9.06 and – per share.
At today's price, the P/E is 19.4 for UNH and 15.7 for VCYT. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 3.5% for UnitedHealth and 21.8% for Veracyte, and the operating margin 5.3% and 17.1%. Revenue was $450B and $582M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.